Danaher Beacons
Yale and UPenn
ADC companion diagnostics
This collaboration between researchers at Yale and University of Pennsylvania, as part of the Translational Breast Cancer Research Consortium, aims to establish a quantitative companion diagnostic test to determine which patients can benefit from next-generation antibody drug conjugates. The work leverages two complementary technologies with improved ability to precisely measure low levels of gene and protein expression.
Stanford University
Smart microscopy
This collaboration aims to leverage the latest findings in spatial biology coupled with cutting-edge AI to make it possible to screen more complex cellular systems, ranging from 2D to 3D and single-cell to multi-cell. The ultimate outcome could be an analysis engine that can detect spatial, proteomic, and metabolic changes in the tumor microenvironment and more accurately predict how tumors will respond to potential therapies.
Johns Hopkins University
Brain injury diagnostics
This collaboration aims to develop new, more sensitive methods for diagnosing mild traumatic brain injury (TBI). The tests will leverage highly sensitive clinical immunoassay technology to evaluate the efficacy of a new biomarker panel intended to help doctors diagnose mild TBI earlier and more precisely. If effective, the approach could also someday be adapted for the diagnosis of other types of brain injury or neurodegenerative diseases.
Cincinnati Children’s
Next-gen toxicity testing
This collaboration aims to improve patient safety and accelerate the development of new therapies by addressing a leading cause of failure in clinical trials. The goal is to develop more streamlined, scalable, and genetically diverse liver organoid technology as a drug toxicity screening solution, so that the biopharma industry is better-positioned be able to deliver better, safer drugs to patients faster.
Innovative Genomics Institute
CRISPR cures
This collaborative center aims to develop gene-editing cures for rare and other diseases on an unprecedented scale. Its approach uses the programmable power of CRISPR, with the goal of permanently addressing hundreds of diseases with a single research, development and regulatory approach – one that could create a new model for future development of a wide range of genomic medicines.
Oxford University
Sepsis subtyping innovation
This partnership is developing a new test to enable precision medicine care for sepsis, a pathological immune response to infection that accounts for one in five deaths globally each year. The test will leverage rapid molecular diagnostic technologies to pinpoint different subtypes of sepsis and allow the development of novel personalized care paths, including which targeted therapies are most likely to help.
University of Pennsylvania
Cell therapy manufacturing
This multi-year collaboration aims to develop new technologies that will improve the consistency of clinical outcomes for patients and overcome manufacturing bottlenecks in the delivery of next generation engineered cell products. Its focus will be on product solutions that address challenges in both yield and quality of cell therapies.
Duke University
Gene therapy innovation
This Beacon focuses on innovation at the intersection of biology and manufacturing, with the long-term goal of fully realizing the promise of gene therapy. It aims to deliver product solutions that address bottlenecks impacting viral vector manufacturing yield and quality.
